Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Guangping Gao
University of Massachusetts Medical School

Follow this and additional works at: http://escholarship.umassmed.edu/cts_retreat

Part of the Genetics and Genomics Commons, Pharmaceutics and Drug Design Commons, Therapeutics Commons, and the Translational Medical Research Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
GENE THERAPY STRATEGIES: AN OVERVIEW
DISCLOSURE

1. G. Gao is a cofounder of Voyager Therapeutics, a biopharmaceutical company and holds equity in the company.

2. G. Gao is an inventor on patents with potential royalties licensed to Voyager and other biopharmaceutical companies.
GT drug development:
- starts with a specific therapeutic agent
- skips the drug discovery phase
PROGRESS IN GENE THERAPY
- DRIVEN BY VECTOR PLATFORM DEVELOPMENT

- First human gene therapy for ADA Via retrovirus (Sept 14, 1990)
- First adenovirus for cystic fibrosis (1993)
- Discovery of AAV8 (2002)
- Gao G entered the field (1994)
- Glybera approved by EMA (2012)
- AAV8 to treat hemophilia B (2011)
- AAV2 gene transfer to treat LCA (2008)
- First AAV for CFTR (November 1995)
- First lentivirus against HIV (2003)
- Clinical trial for X-linked ALD (2014)
- CAR-T-cell therapy (2011)
COMMERCIALIZATION OF GENE THERAPY
- RAPID TRANSFORMATION IN THE PAST FEW YEARS

More than 200 gene therapy companies globally
WHY UMMS?

- A WORLD LEADER IN RNAi, DEGENERATIVE NEUROLOGICAL DISEASE RESEARCH & AAV GENE THERAPY

• Our faculty have made key advances
  – World leading scientists in RNAi research (Mello, Ambros, & Zamore)
  – World leading physician scientists in neurodegenerative disorders
    ➢ Brown for Amyotrophic Lateral Sclerosis
    ➢ Aronin for Huntington Disease
  – World leading rAAV gene therapy scientists
    ➢ First to discover novel primate AAVs for efficient and stable gene transfer (Gao, 2002)
    ➢ First to use AAV gene therapy in patients with 4 INDs (Flotte 1995)

• Horae Gene Therapy Center
  – A >12,000 Ft² state-of-art research facility on the 6th floor of Albert Sherman Building
  – Research home for 15 faculty and affiliated faculty members, > 60 trainees and staff
IMPORTANT MILESTONES IN FOUNDING & GROWING OF VOYAGER

- Initially approached by 3rd Rock Venture
- Re-engagement by 3rd Rock Venture
- Voyager signed license agreement with UMMS for RNAi and rAAV technology platforms
- Continued discussions w/t 3RV on “AAVian”
- Voyager secured $60 M series B funding from “Crossover” investors
- $845 M committed by Sanofi/Genzyme for strategic collaboration w/t Voyager in CNS gene therapy
- $45 M series A funding by 3RV & formally launching of Voyager
- Voyager IPO $225 M cash
Company Founders

Voyager was founded by world leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience.

Krystof Bankiewicz, M.D., Ph.D.
Kinetics Foundation Chair in Translational Research and Professor in Residence of Neurological Surgery and Neurology, University of California at San Francisco

Guangping Gao, Ph.D.
Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS

Mark Kay, M.D., Ph.D.
Dennis Farrey Family Professor, Head, Division of Human Gene Therapy, Departments of Pediatrics and Genetics, Stanford University School of Medicine

Phillip Zamore, Ph.D.
Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Co-Director of the RNA Therapeutics Institute, University of Massachusetts Medical School (UMMS)
Company Highlights

Robust product engine to engineer, optimize, manufacture and deliver AAV gene therapies

Pipeline of five programs for severe CNS diseases

Lead program, VY-AADC01, for advanced Parkinson’s disease with human POC expected in H2:2016

Strategic collaboration with Genzyme — gene therapy “know-how”

Strong financial position with ~$225 million of cash following IPO in November 2015, no debt

Management team and scientific founders that have pioneered significant advances in AAV gene therapy and neuroscience, and have extensive CNS drug development expertise (Steve Paul, MD, CEO)
Treating Severe CNS Diseases with AAV Gene Therapy

Why CNS?

- Significant unmet medical need
- Genetically-validated targets
- Targeted delivery to regions of the brain & broader delivery to the spinal cord is achievable
- Durable transgene expression as CNS cells are terminally differentiated
- Immune-privileged site

Why AAV?

- Ability to target a variety of tissue & cell types within the CNS
- >1,300 patients (200 in CNS) treated, no AAV-related SAEs to date
- AAV does not readily integrate into the target cell genome, reducing potential for oncogenesis
- Ability to manufacture at commercial quality and scale
# Product Engine Driving Pipeline of AAV Gene Therapies

## Product Engine

- **Dosing & Delivery Techniques**
- **Vector Engineering & Optimization**
- **Process R&D & Manufacturing**

## Pipeline of 5 Programs

<table>
<thead>
<tr>
<th>Program</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>VY-AADC01</td>
<td>Advanced Parkinson’s Disease</td>
<td></td>
<td>U.S. Genzyme</td>
</tr>
<tr>
<td>VY-SOD101</td>
<td>Monogenic Form of ALS</td>
<td></td>
<td>Ex-U.S. Genzyme (option)</td>
</tr>
<tr>
<td>VY-FXN01</td>
<td>Friedreich’s Ataxia</td>
<td></td>
<td>Genzyme (option)</td>
</tr>
<tr>
<td>VY-HTT01</td>
<td>Huntington’s Disease</td>
<td></td>
<td>Genzyme (option to co-U.S.)</td>
</tr>
<tr>
<td>VY-SMN101</td>
<td>Spinal Muscular Atrophy</td>
<td></td>
<td>Genzyme (option to worldwide)</td>
</tr>
</tbody>
</table>
Commercial Scale AAV Manufacturing Capabilities

**Process R&D**
- Process R&D center at Voyager’s headquarters
- Research grade baculovirus / Sf9 production system
- Up to 250L bioreactor capacity
- Proprietary reagents for new capsids and constructs

**Large Scale Research Capacity**
- Collaboration with UMass Medical School
- Research grade baculovirus / Sf9 production system
- Up to 500L bioreactor capacity

**Commercial Scale cGMP Capacity**
- Collaboration with MassBiologics
- cGMP baculovirus / Sf9 production system
- Up to 1,000L bioreactor capacity
- Voyager retains IP and key process know-how
Robust Strategic Collaboration with UMMS

Voyager and UMMS collaborate under a broad strategic partnership to advance AAV gene therapy research, manufacturing and education

**Research Collaboration**
- Pilot grant program focused on understanding & optimizing AAV vectors for therapeutic use
- Licenses and sponsored research focused on novel AAV technology
- Opportunities for UMMS participation in Voyager clinical trials

**Production & Manufacturing**
- AAV vector supply from the UMMS Gene Therapy Vector Core to support Voyager research projects
- Partnership with MassBiologics to advance AAV process development & GMP production for Voyager product programs

**Educational Support**
- Postdoctoral training program
- Sponsorship of annual lecture series on AAV-mediated gene therapy
- Opportunities for Voyager to support graduate fellowships in the area of central nervous system AAV gene therapy